MedTech (R)evolution

Panel Session

Diagnostics

The Democratization of Personalized Medicine – Bringing it Closer to the Community

Panel Session Moderator(s)

• 

  David Parker, PhD

  Senior Vice President, Diagnostics Solutions
  Precision For Medicine

Panel Session Speaker(s)

• SE

  Sheryl Elkin, PhD

  Chief Scientific Officer
  N-of-One, Inc.
• PG

  Paul Gerrard, MD

  Medical Director and MolDX Director of Clinical Science
  Palmetto GBA
• 

  Stephen Schleicher, MD, MBA

  Medical Oncologist; Chair, Quality and Value Committee
  Tennessee Oncology/OneOncology

Genomics-guided precision medicine has become more common practice for patient risk predisposition screening, disease diagnosis, patient stratification, targeted therapy treatment decision support, and prognostics in cancer and rare diseases. While there are emerging wet lab standards, there continues to be a lack of consistency in the analysis, interpretation and reporting of these types of genomic tests that is slowing their diffusion in broader clinical practice. Further, healthcare providers and the testing laboratories that serve them have made limited progress on integrating genomic testing results with patient clinical and outcomes data – which is critical to achieving real genomics guided precision medicine.

This panel will discuss the current state of molecular diagnostic and genomics testing and how healthcare providers, laboratories, pharma, and payers can work more collaboratively together to establish improved protocols and methods of test interpretation and reporting for clinical decision support, integration of molecular and genomic results with patient clinical data, and the development of RWD-RWE evidence to accelerate the development of high-value diagnostics that apply genetic information, and democratize the benefits of genomics-guided precision medicine.